Related Experiment Video
Updated: Apr 26, 2026
09:19
In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
9.6K
[Chronic thromboembolic pulmonary hypertension--a position paper]
H Wilkens1, I Lang2, T Blankenburg3
1Klinik für Innere Medizin V, Universitätsklinikum des Saarlandes, Homburg.
Deutsche Medizinische Wochenschrift (1946)
|August 2, 2014
Summary
This paper outlines chronic thromboembolic pulmonary hypertension (CTEPH) diagnosis and treatment, emphasizing pulmonary endarterectomy (PEA) for operable cases. PEA offers better long-term survival and quality of life compared to medical therapy for CTEPH patients.
Area of Science:
- Cardiology
- Pulmonology
- Vascular Surgery
Background:
- Summarizes current developments in chronic thromboembolic pulmonary hypertension (CTEPH).
- Based on 2013 Nice 5th World Symposium on Pulmonary Hypertension guidelines.
- Addresses open questions in CTEPH patient management.
Framework:
- Recommends echocardiography and cardiopulmonary exercise testing for suspected CTEPH.
- Ventilation/perfusion scan is the primary imaging screening tool.
- Emphasizes multidisciplinary expert center evaluation for treatment decisions.
Implementation:
- Pulmonary endarterectomy (PEA) is the preferred treatment for operable CTEPH.
- Medical therapy is reserved for inoperable cases or post-PEA residual disease.
- Initiate medical therapy only if PEA is not an option.
Implications:
- CTEPH patients undergoing PEA demonstrate superior long-term survival rates.
- PEA treatment leads to an improved quality of life in CTEPH patients.
- Highlights the importance of surgical intervention for optimal CTEPH outcomes.
Related Concept Videos
01:19Pulmonary Embolism I: Introduction
34
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
34
01:29Pulmonary Embolism I: Introduction
1.5K
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
1.5K
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
746
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
746
01:27Pulmonary Embolism III: Nursing Management
750
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
750
01:30Pulmonary Hypertension: Classification and Pathogenesis
902
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
902
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
688
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
688